Human Immunodeficiency Virus 1 Preferentially Fuses with pH-Neutral Endocytic Vesicles in Cell Lines and Human Primary CD4+ T-Cells.
endocytosis
membrane fusion
pH-sensing
single virus tracking
virus labeling
Journal
ACS nano
ISSN: 1936-086X
Titre abrégé: ACS Nano
Pays: United States
ID NLM: 101313589
Informations de publication
Date de publication:
12 09 2023
12 09 2023
Historique:
medline:
14
9
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
ppublish
Résumé
Despite extensive efforts, the principal sites of productive HIV-1 entry in different target cells─plasma membrane (PM) vs endosomes─remain controversial. To delineate the site(s) of HIV-1 fusion, we implemented a triple labeling approach that involves tagging pseudoviruses with the fluid-phase viral content marker, iCherry, the viral membrane marker, DiD, and the extraviral pH sensor, ecliptic pHluorin. The viral content marker iCherry is released into the cytoplasm upon virus-cell fusion irrespective of the sites of fusion. In contrast, the extent of dilution of the membrane marker upon fusion with the PM (loss of signal) vs the endosomal membrane (no change in punctate DiD appearance) discriminates between the principal sites of viral fusion. Additionally, ecliptic pHluorin incorporated into the viral membrane reports whether virus fusion occurs in acidic endosomes. Real-time single virus imaging in living HeLa-derived cells, a CD4+ T-cell line, and activated primary human CD4+ T-cells revealed a strong (80-90%) HIV-1 preference for fusion with endosomes. Intriguingly, we observed HIV-1 fusion only with pH-neutral intracellular vesicles and never with acidified endosomes. These endocytic fusion events are likely culminating in productive infection since endocytic inhibitors, such as EIPA, Pitstop2, and Dynasore, as well as a dominant-negative dynamin-2 mutant, inhibited HIV-1 infection in HeLa-derived and primary CD4+ T-cells. Furthermore, the inhibition of endocytosis in HeLa-derived cells promoted hemifusion at the PM but abrogated complete fusion. Collectively, these data reveal that the primary HIV-1 entry pathway in diverse cell types is through fusion with pH-neutral intracellular vesicles.
Identifiants
pubmed: 37589658
doi: 10.1021/acsnano.3c05508
pmc: PMC10510587
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
17436-17450Subventions
Organisme : NIAID NIH HHS
ID : R37 AI150453
Pays : United States
Références
Ear Nose Throat J. 1990 Jan;69(1):63-71
pubmed: 1968002
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Antimicrob Agents Chemother. 2013 Sep;57(9):4172-80
pubmed: 23774428
Nat Protoc. 2014 Jan;9(1):182-92
pubmed: 24385148
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6812-7
pubmed: 17412836
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E28-E36
pubmed: 27974607
J Biol Chem. 2017 Dec 8;292(49):20196-20207
pubmed: 29046351
J Virol. 2005 Feb;79(3):1581-94
pubmed: 15650184
Nat Chem Biol. 2019 Mar;15(3):259-268
pubmed: 30643282
Virology. 2003 Jun 5;310(2):319-32
pubmed: 12781719
Cell Stem Cell. 2018 Dec 6;23(6):820-832.e9
pubmed: 30416070
J Cell Biol. 2003 Aug 4;162(3):443-55
pubmed: 12885763
Traffic. 2017 Jun;18(6):392-410
pubmed: 28321960
PLoS Pathog. 2022 Aug 15;18(8):e1010625
pubmed: 35969633
J Virol. 2004 Apr;78(8):4120-33
pubmed: 15047828
PLoS One. 2013 Aug 09;8(8):e71002
pubmed: 23951066
Methods Enzymol. 2008;438:77-93
pubmed: 18413242
Virol Sin. 2014 Jun;29(3):139-47
pubmed: 24938714
Br J Pharmacol. 2018 Sep;175(18):3640-3655
pubmed: 29953580
J Virol. 2014 Dec;88(24):13956-70
pubmed: 25253335
J Virol. 2007 Nov;81(22):12596-607
pubmed: 17728233
Cell. 2009 May 1;137(3):433-44
pubmed: 19410541
Vaccine. 2007 Nov 19;25(47):8036-48
pubmed: 17936444
J Virol. 1999 Nov;73(11):8966-74
pubmed: 10516002
J Virol. 2002 Nov;76(22):11440-6
pubmed: 12388705
Cell. 1987 Jun 5;49(5):659-68
pubmed: 3107838
Cell. 1988 Sep 9;54(6):865-74
pubmed: 3261635
EMBO J. 1988 Feb;7(2):513-8
pubmed: 3259178
J Virol. 2005 May;79(9):5705-12
pubmed: 15827185
J Virol. 2001 Nov;75(22):11166-77
pubmed: 11602756
Retrovirology. 2011 Dec 06;8:99
pubmed: 22145853
PLoS Pathog. 2014 Apr 03;10(4):e1004048
pubmed: 24699674
PLoS One. 2016 Feb 10;11(2):e0148944
pubmed: 26863211
Mol Biol Cell. 2001 Sep;12(9):2578-89
pubmed: 11553700
Adv Exp Med Biol. 2012;726:223-42
pubmed: 22297516
J Virol. 2013 Jul;87(14):8110-23
pubmed: 23678185
Cell. 2011 Aug 5;146(3):471-84
pubmed: 21816279
Trends Microbiol. 2010 Dec;18(12):543-51
pubmed: 20965729
J Biol Chem. 2002 May 10;277(19):17291-9
pubmed: 11782464
Biochemistry. 2015 Nov 17;54(45):6796-805
pubmed: 26506247
Biomolecules. 2023 Jun 03;13(6):
pubmed: 37371517
J Cell Sci. 2013 Nov 15;126(Pt 22):5305-12
pubmed: 24046449
Virology. 2011 Jan 20;409(2):234-50
pubmed: 21056892
Curr Top Membr. 2011;68:81-106
pubmed: 21771496
J Virol. 1994 Feb;68(2):1179-85
pubmed: 8289347
Genes Dev. 2000 Nov 1;14(21):2677-88
pubmed: 11069884
PLoS Pathog. 2013;9(6):e1003431
pubmed: 23785290
J Cell Biol. 2000 Oct 16;151(2):F9-14
pubmed: 11038194
Cell Host Microbe. 2011 Dec 15;10(6):551-62
pubmed: 22177560
Mol Cancer. 2013 Jan 17;12:4
pubmed: 23327284
Biochem J. 2011 Mar 15;434(3):559-69
pubmed: 21175427
Viruses. 2019 Jan 25;11(2):
pubmed: 30691001